ERBB2 and cholangiocarcinoma: Because lapatinib exerts anti-tumor effects on HER2-overexpressed CCA cells while simultaneously overcoming ABCB1–mediated chemoresistance, this proves that a lapatinib-gemcitabine combination-based therapy can be significantly more effective at treating HER2-positive CCA cases.